IP Library Granted Patent US 8,163,695
Granted Patent B2
US 8,163,695 · App. 11/924,154 · Granted Apr 24, 2012

Formulations of human growth hormone comprising a non-naturally encoded amino acid

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,163,695
App. No.
11/924,154
Granted
Apr 24, 2012
Kind
B2
Abstract

Formulations of modified human growth hormone polypeptides are provided.

Claims (4)

1. A pharmaceutical formulation of a human growth hormone (hGH) variant comprising one or more non-naturally encoded amino acids wherein the non-naturally encoded amino acids are substituted at positions selected from the group consisting of 35, 92, 131, 134, 143 and 145 of SEQ ID NO: 2 and the non-naturally encoded amino acids have the structure:

wherein the R group is any substituent other than one used in the twenty natural amino acids, wherein each non-naturally encoded amino acid is linked to a water soluble polymer and wherein the serum half-life of the linked variant is at least two-fold greater than the serum half-life of a wild type hGH protein and wherein said formulation has a concentration between 8 mg/mL and 14 mg/mL.

2. A pharmaceutical formulation of a human growth hormone (hGH) variant comprising one or more non-naturally encoded amino acids wherein the non-naturally encoded amino acids are substituted at positions selected from the group consisting of 35, 92, 131, 134, 143 and 145 of SEQ ID NO: 2 and the non-naturally encoded amino acids have the structure:

wherein the R group is any substituent other than one used in the twenty natural amino acids, wherein each non-naturally encoded amino acid is linked to a water soluble polymer, and wherein the serum half-life of the linked variant is at least two-fold greater than the serum half-life of a wild type hGH protein and wherein said formulation has a concentration between 8 mg/mL and 10 mg/mL and said formulation's viscosity allows for 1 mL to be injected through a 27 gauge needle with 4 lbs of force in 5 seconds or less.

Assignments (2)
SECURITY INTEREST Recorded May 13, 2024
From: RINGCENTRAL, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 067389/0152 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 6, 2008
From: HAYS, ANNA-MARIA; BUECHLER, YING; LITZINGER, DAVID C.
To: AMBRX, INC.
Reel/Frame 020613/0370 →